AKBA
Price
$3.96
Change
+$0.27 (+7.32%)
Updated
Jun 6, 04:09 PM (EDT)
Capitalization
971.75M
55 days until earnings call
XERS
Price
$4.57
Change
+$0.11 (+2.47%)
Updated
Jun 6, 04:46 PM (EDT)
Capitalization
714.29M
61 days until earnings call
Interact to see
Advertisement

AKBA vs XERS

Header iconAKBA vs XERS Comparison
Open Charts AKBA vs XERSBanner chart's image
Akebia Therapeutics
Price$3.96
Change+$0.27 (+7.32%)
Volume$7.09K
Capitalization971.75M
Xeris Biopharma Holdings
Price$4.57
Change+$0.11 (+2.47%)
Volume$2.86K
Capitalization714.29M
AKBA vs XERS Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. XERS commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and XERS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (AKBA: $3.70 vs. XERS: $4.46)
Brand notoriety: AKBA and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 120% vs. XERS: 77%
Market capitalization -- AKBA: $971.75M vs. XERS: $714.29M
AKBA [@Biotechnology] is valued at $971.75M. XERS’s [@Biotechnology] market capitalization is $714.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKBA and XERS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 2 TA indicator(s) are bullish while XERS’s TA Score has 5 bullish TA indicator(s).

  • AKBA’s TA Score: 2 bullish, 4 bearish.
  • XERS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XERS is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а +22.92% price change this week, while XERS (@Biotechnology) price change was -11.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

AKBA is expected to report earnings on Jul 31, 2025.

XERS is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($972M) has a higher market cap than XERS($714M). AKBA YTD gains are higher at: 94.737 vs. XERS (31.563). AKBA has higher annual earnings (EBITDA): 6.59M vs. XERS (-13.99M). AKBA has more cash in the bank: 113M vs. XERS (71.6M). AKBA has less debt than XERS: AKBA (54.1M) vs XERS (271M). XERS has higher revenues than AKBA: XERS (203M) vs AKBA (185M).
AKBAXERSAKBA / XERS
Capitalization972M714M136%
EBITDA6.59M-13.99M-47%
Gain YTD94.73731.563300%
P/E RatioN/AN/A-
Revenue185M203M91%
Total Cash113M71.6M158%
Total Debt54.1M271M20%
FUNDAMENTALS RATINGS
AKBA vs XERS: Fundamental Ratings
AKBA
XERS
OUTLOOK RATING
1..100
2961
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3542
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKBA's Valuation (76) in the Biotechnology industry is in the same range as XERS (91) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to XERS’s over the last 12 months.

XERS's Profit vs Risk Rating (83) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that XERS’s stock grew similarly to AKBA’s over the last 12 months.

XERS's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as AKBA (99) in the Biotechnology industry. This means that XERS’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (35) in the Biotechnology industry is in the same range as XERS (42) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to XERS’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAXERS
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 22 days ago
85%
Declines
ODDS (%)
Bearish Trend 26 days ago
86%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FESOX26.73N/A
N/A
First Eagle Overseas C
IWEDX13.35N/A
N/A
Voya Large Cap Value W
MADFX33.70N/A
N/A
Matrix Advisors Dividend
JIJAX14.62N/A
N/A
JHancock International Dynamic Gr A
DCSYX62.04-0.06
-0.10%
Davis Balanced Fund Y

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+1.65%
XERS - AKBA
42%
Loosely correlated
+0.68%
ATOS - AKBA
40%
Loosely correlated
+0.32%
ADAP - AKBA
40%
Loosely correlated
+0.25%
ABOS - AKBA
39%
Loosely correlated
-0.47%
FHTX - AKBA
39%
Loosely correlated
-1.19%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
+0.68%
TRDA - XERS
51%
Loosely correlated
+2.14%
CGON - XERS
47%
Loosely correlated
+0.23%
XNCR - XERS
45%
Loosely correlated
+0.22%
YMAB - XERS
45%
Loosely correlated
+3.02%
KRYS - XERS
44%
Loosely correlated
+0.53%
More